SESSION TITLE: Tuesday Medical Student/Resident Case Report Posters SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: 10/22/2019 01:00 PM - 02:00 PM INTRODUCTION: Malignant Pleural Mesothelioma (MPM) is one of the most rare and subtle malignancies with a very poor prognosis. Diagnosis is not simple and needs biopsy for confirmation. It can present as three histologic subtypes. Diagnosis is often made late when at an advanced stage due to the generalized symptoms and non-specific findings. We present a case of a rather healthy male patient with no asbestos exposure who initially was presumed to have pneumonia and later diagnosed with biphasic MPM post pleural biopsy. CASE PRESENTATION: A 67 year old former smoker male patient presented with the complaint of a productive cough with scant white sputum for five days which was associated with some chest pain and dyspnea on exertion. No known asbestos exposure. Chest Xray (F1) revealed right lower lung infiltrate and large pleural effusion, but there was no leukocytosis or fever. Initial impression was parapneumonic effusion and empiric antibiotics were given. CT chest (F2) showed a loculated right sided pleural effusion with an irregular infiltrate at the right lung base with pleural thickening and lymphadenopathy. Pleural fluid was positive for malignant cells and suspected for adenocarcinoma vs. mesothelioma. A month later there was worsening right sided pleural effusion requiring drainage. Bronchoscopy, right VATS, and debridement of pleural space were done and biopsy of the right parietal pleural implants showed Stage IV MPM. Biopsy showed neoplastic cells positive for CK 5/6, calretinin, WT-1, D240, CK 7 and negative for BER-EP4, MOC-31, TTF-1, P40, Napsin and CK20 which was consistent with biphasic malignant mesothelioma. PET revealed bone metastasis. Cisplastin and Premetrexed was started. DISCUSSION: MPM is a rare malignancy which presents with gradual nonspecific symptoms. Symptoms may be present for months prior to a diagnosis is made. Metastasis is not common but could rarely involve bone, liver, and CNS. Imaging is the initial mode for evaluation. Findings include unilateral pleural effusion or mass or pleural thickening or pleural thickening and/or calcification. Thoracentesis is done but does not always give enough tissue to make a diagnosis. Only tissue biopsy confirms the diagnosis so a VATS biopsy or open thoracotomy is needed. Histologic subtypes include: epithelioid, sarcomatoid, or biphasic. The TNM staging system is used for staging and for possible surgical resection and treatment. Prognosis is poor and survival is 9 to 17 months post diagnosis. Biphasic and sarcamoid subtypes are worse and clinical suspicion is higher with positive asbestos exposure. CONCLUSIONS: The subtle clinical presentation of MPM may cause a delay in the diagnosis. Positive asbestos exposure is not needed for suspicion. Medical professions need to be aware that a thorough clinical history, high level of suspicion with histological and immunohistochemical characteristics is required for definitive diagnosis. Reference #1: Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36:1343. Reference #2: Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723. Reference #3: Ahamad A, Stevens CW, Smythe WR, et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 2003; 9:476. DISCLOSURES: No relevant relationships by Abhinav Agrawal, source=Web Response No relevant relationships by Theo Trandafirescu, source=Web Response No relevant relationships by Milana Zirkiyeva, source=Web Response
Read full abstract